Center for Reproductive Medicine and Obstetrics and Gynecology, Drum Tower Clinic Medical College of Nanjing Medical University, Nanjing, China.
Center for Reproductive Medicine and Obstetrics and Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, China.
Front Endocrinol (Lausanne). 2023 Mar 1;14:1102706. doi: 10.3389/fendo.2023.1102706. eCollection 2023.
To investigate the effects of two protocols (hormone replacement therapy (HRT) alone or in combination with tamoxifen) on the endometrium and pregnancy outcome of patients with thin endometrium in frozen-thawed embryo transfer (FET) cycles.
A total of 465 infertile patients with thin endometrium who underwent FET between January 2020 to June 2021 at the Drum Tower Hospital affiliated with Nanjing University Medical School were retrospectively analyzed. A total of 187 patients were given tamoxifen in addition to HRT (TMXF-HRT group), whereas 278 patients were given only HRT (HRT group). Clinical data were compared between the two groups, including general characteristics, endometrial thickness, and clinical pregnancy outcomes.
There were no significant differences in baseline characteristics of all enrolled patients between two groups. Serum progesterone (P) was higher in HRT group than in the TMXF-HRT group (0.28 ± 0.53 ng/mL . 0.15 ± 0.25 ng/mL, P = 0.002). There was a significant increase in endometrial thickness in the TMXF-HRT group compared with the HRT group (OR: 1.54, 95% CI: 1.32-1.75, P < 0.001). There were no significant differences in the clinical pregnancy rate, embryo implantation rate, early miscarriage rate, or live birth rate between these two groups.
Although tamoxifen when used in combination with hormone replacement therapy can significantly increase endometrial thickness, it may not have a role in improving the pregnancy outcomes of patients with thin endometrium undergoing FET cycles.
探讨两种方案(单独使用激素替代疗法(HRT)或联合使用他莫昔芬)对冷冻胚胎移植(FET)周期中薄型子宫内膜患者的子宫内膜和妊娠结局的影响。
回顾性分析了 2020 年 1 月至 2021 年 6 月在南京大学医学院附属鼓楼医院接受 FET 的 465 例薄型子宫内膜不孕患者。187 例患者除 HRT 外还给予他莫昔芬(TMXF-HRT 组),278 例患者仅给予 HRT(HRT 组)。比较两组患者的临床资料,包括一般特征、子宫内膜厚度和临床妊娠结局。
两组患者的基线特征无统计学差异。HRT 组血清孕激素(P)水平高于 TMXF-HRT 组(0.28 ± 0.53 ng/mL vs. 0.15 ± 0.25 ng/mL,P = 0.002)。TMXF-HRT 组子宫内膜厚度较 HRT 组明显增加(OR:1.54,95%CI:1.32-1.75,P < 0.001)。两组患者的临床妊娠率、胚胎着床率、早期流产率和活产率均无统计学差异。
虽然他莫昔芬联合激素替代疗法可显著增加子宫内膜厚度,但对改善 FET 周期中薄型子宫内膜患者的妊娠结局可能无作用。